The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Rapper Fat Joe recently shared how he’s been using the Type 2 diabetes medication Ozempic to maintain his 200-pound weight ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
In response to rising demand for weight loss medications, WeightWatchers has launched a low-cost alternative to ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...
The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback